agilon health, inc. The company is headquartered in Long Beach, California.
| Revenue (TTM) | $6.00B |
| Gross Profit (TTM) | $179.47M |
| EBITDA | $-85.93M |
| Operating Margin | 1.80% |
| Return on Equity | -36.10% |
| Return on Assets | -3.94% |
| Revenue/Share (TTM) | $360.18 |
| Book Value | $16.72 |
| Price-to-Book | 6.80 |
| Price-to-Sales (TTM) | 0.32 |
| EV/Revenue | 0.284 |
| EV/EBITDA | -104.52 |
| Quarterly Earnings Growth (YoY) | 301.00% |
| Quarterly Revenue Growth (YoY) | 5.90% |
| Shares Outstanding | $16.80M |
| Float | $10.93M |
| % Insiders | 5.04% |
| % Institutions | 98.51% |
Volatility is currently expanding
Agilon Health NYSE: AGL raised its full-year 2026 outlook after reporting third-quarter results that exceeded its guidance, driven by higher risk-adjustment revenue, clinical program performance and favorable medical cost development in the first half of the year.
Here is how Agilon Health (AGL) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.
Here is how Agilon Health (AGL) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 461-5787 for U.S. participants and +1 (585) 542-9983 for international participants and ref.
Here is how Agilon Health (AGL) and Illumina (ILMN) have performed compared to their sector so far this year.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will now participate in a fireside chat at the 2026 Jefferies Healthcare Services and Technology Conference at 4:00pm ET on Monday, September 14, 2026. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the “Events & Presentations” section o.
Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
agilon Health delivered a strong Q2 2026 with revenue of $1.49B, a $250M YoY medical margin swing, and raised FY26 guidance across all key metrics. AGL's operational turnaround is supported by improved cost trends, enhanced data pipelines, and clinical pathway execution, notably reducing inpatient first-diagnosis rates from 25% to under 5%. Balance sheet strength is evident with over $220M net cash, while disciplined membership management supports ongoing profitability.
Agilon Health NYSE: AGL reported second-quarter results that exceeded its guidance for medical margin and adjusted EBITDA, citing stronger risk-adjustment revenue, favorable medical-cost development and progress in its clinical and quality initiatives. The company also raised its full-year 2026 outlook.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the second quarter ended June 30, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. “Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence i.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AGL and any ticker you trade — then tracks every position and per-strategy win rate.
